PYC THERAPEUTICS LIMITED

2.75%

$1.24

Market Cap $723.2M

Healthcare Biotechnology

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company... PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.More

BPH Energy (ASX:BPH) continues court battle while eastern states energy crisis worsens

Latest Threads

Tag

Subject

PYC

PYC - General Discussion

16 17 18

17:05

1.0K

530K

17:05

Last post standalone

1.0K

530K

PYC

Ann: Q3 Investor Webinar 1 August 2025

28/07/25

1.2K

28/07/25

Last post Fat Harrys Cat

1.2K

PYC

PYC Filed Another Patent

25/07/25

37K

25/07/25

Last post Linsanity

37K

PYC

Ann: Quarterly Activities/Appendix 4C Cash Flow Report

25/07/25

4.8K

25/07/25

Last post Counterfiat

4.8K

PYC

Barrenjoey NASDAQ and PYC

17/07/25

14K

17/07/25

Last post Fat Harrys Cat

14K

PYC

Ann: Approval to Progress Kidney Disease Trial to Next Stage

14/07/25

2.7K

14/07/25

Last post actionnaire

2.7K

PYC Biotech

PYC Chart and Technical Analysis

4 5 6

09/07/25

328

185K

09/07/25

Last post Fat Harrys Cat

328

185K

PYC

Ann: First Subject Dosed in PKD Clinical Trial

05/07/25

31K

05/07/25

Last post actionnaire

31K

See All Discussions

Timeline

Q3 Investor Webinar 1 August 2025
28 Jul 08:59	Share

Quarterly Activities/Appendix 4C Cash Flow Report
21 Jul 08:42	Share

Approval to Progress Kidney Disease Trial to Next Stage
07 Jul 08:57	Share

Fourth Drug Program Progressing to Human Trials
27 Jun 09:11	Share

FDA Alignment on Registrational Trial Design RP11 Program
23 Jun 08:57	Share

SRC Approves Dose Escalation in ADOA Clinical Trial
11 Jun 09:17	Share

Investor Webinar Presentation
30 May 08:59	Share

Approval to Escalate Dosing in Kidney Disease Trial
26 May 09:13	Share

Notification of cessation of securities - PYC
23 May 16:29	Share

Q2 Investor Webinar 30 May 2025
13 May 09:32	Share

Foundation Fighting Blindness Presentation Materials
02 May 08:31	Share

Change in substantial holding
28 Apr 16:33	Share

Presentation of Clinical Proof of Concept in Lead Program
28 Apr 09:02	Share

Quarterly Activities/Appendix 4C Cash Flow Report
24 Apr 08:48	Share

Application for quotation of securities - PYC
23 Apr 17:44	Share

Completion of Entitlement Offer
17 Apr 08:35	Share

First Subject Dosed in PKD Clinical Trial
10 Apr 08:45	Share

Placement of Shortfall
09 Apr 09:45	Share

Investor Webinar Presentation
28 Mar 09:17	Share

Application for quotation of securities - PYC
21 Mar 09:40	Share

Q1 Investor Webinar 28 March 2025
21 Mar 09:38	Share

Completion of Retail Entitlement Offer
18 Mar 14:19	Share

Change of Director's Interest Notice
27 Feb 18:43	Share

Ceasing to be a substantial holder
27 Feb 16:22	Share

Half Yearly Report and Accounts
27 Feb 16:16	Share

Application for quotation of securities - PYC
26 Feb 10:45	Share

Despatch of Notice to Ineligible Retail Shareholders
24 Feb 12:12	Share

Despatch of Retail Offer Document
24 Feb 12:10	Share

Retail Entitlement Offer Booklet
24 Feb 12:09	Share

Completion of Institutional Entitlement Offer
19 Feb 09:45	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.24		Change -0.035(2.75%)		Mkt cap ! $723.2M

Open	High	Low	Value	Volume
$1.27	$1.27	$1.22	$162.1K	130.3K

Buyers (Bids)

No.	Vol.	Price($)
2	3818	$1.22

Sellers (Offers)

Price($)	Vol.	No.
$1.24	956	1

View Market Depth

No.	Vol.	Price($)
2	3818	1.220
1	850	1.200
1	30000	1.195
1	10000	1.190
1	17583	1.185

Price($)	Vol.	No.
1.240	956	1
1.280	4115	1
1.290	7500	1
1.300	8200	2
1.310	7427	1

Last trade - 16.10pm 31/07/2025 (20 minute delay)


Last $1.23		Change -0.035 ( 3.12 %)
Open	High	Low	Volume
$1.25	$1.27	$1.22	20719
Last updated 15.59pm 31/07/2025 ?

PYC (ASX) Chart

PYC THERAPEUTICS LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

PYC Therapeutics (ASX:PYC) lands FDA clearance for first human trials of RP11 treatment drug

06 Mar 2023 13:04 (AEDT)

Latest Articles

PYC Therapeutics jumps just shy of +4% as second-stage blindness drug study greenlit

PYC Therapeutics (ASX:PYC) has jumped on Friday as it moves on the the next stage of its escalating single-dose study using its drug PYC-001 to treat a genetic children’s disease causing blindness.(Most gains, however, were quickly sold off.)Autosomal Dominant Optic Atrophy (ADOA)...

Scientific conference spotlights PYC's work on blindness disease treatment

PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat Retinitis Pigmentosa type 11 presented in Singapore

PYC Therapeutics moves into final stage of child blindness study

PYC has been approved to escalate doses of its drug candidate VP-001, treating Retinitis Pigmentosa 11, in a second patient cohort.

Buyers (Bids)

Sellers (Offers)

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

A new NASDAQ listing for a key player in the global critical minerals space

Top Stories

Featured News